Vectibix (panitumumab) Important Safety Information from Amgen as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 18/07/2012

 

Problem Or Issue:
Important Safety Information communication from Amgen on the association of panitumumab with life-threatening and fatal infectious complications of severe skin reactions including necrotising fasciitis.

Important Safety Information Vectibix (panitumumab)


« Back